NBIX Latest News

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

prnewswire.com — Mar 26, 2026

Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibi

Neurocrine Biosciences, Inc. (NBIX) Presents at Stifel 2026 Virtual CNS Forum Transcript

seekingalpha.com — Mar 17, 2026

Neurocrine Biosciences, Inc.

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

prnewswire.com — Mar 17, 2026

SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.

CreativeOne Wealth LLC Has $1.10 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

defenseworld.net — Mar 12, 2026

CreativeOne Wealth LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 34.

Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

prnewswire.com — Mar 10, 2026

SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will partic